Benchmark Reiterates Buy on Nutex Health, Maintains $2.5 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bill Sutherland has reiterated a 'Buy' rating on Nutex Health (NASDAQ:NUTX) and maintained a price target of $2.5.
August 29, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst has reiterated a 'Buy' rating on Nutex Health, maintaining a price target of $2.5.
The reiteration of a 'Buy' rating by a Benchmark analyst and the maintenance of a $2.5 price target indicates a positive outlook for Nutex Health. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100